PubMed

APOBEC3G & HTLV-1: inhibition without deamination.

Strebel K.

Retrovirology. 2005 May 29;2:37.PMID: 15921532 [PubMed - indexed for MEDLINE]Related articlesFree article

APOBEC3G targets human T-cell leukemia virus type 1.

Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T.

Retrovirology. 2005 May 19;2:32.PMID: 15943885 [PubMed - indexed for MEDLINE]Related articlesFree article

APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.

Holmes RK, Koning FA, Bishop KN, Malim MH.

J Biol Chem. 2007 Jan 26;282(4):2587-95. Epub 2006 Nov 22.PMID: 17121840 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.

Kremer M, Schnierle BS.

Curr HIV Res. 2005 Oct;3(4):339-44. Review.PMID: 16250885 [PubMed - indexed for MEDLINE]Related articles

Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.PMID: 15721369 [PubMed - indexed for MEDLINE]Related articles

HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.

Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J.

J Biol Chem. 2005 Mar 11;280(10):8765-75. Epub 2004 Dec 20.PMID: 15611076 [PubMed - indexed for MEDLINE]Related articlesFree article

Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.

Nguyen DH, Gummuluru S, Hu J.

J Virol. 2007 May;81(9):4465-72. Epub 2007 Feb 21.PMID: 17314171 [PubMed - indexed for MEDLINE]Related articlesFree article

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K.

J Virol. 2003 Nov;77(21):11398-407.PMID: 14557625 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.

Bishop KN, Holmes RK, Malim MH.

J Virol. 2006 Sep;80(17):8450-8.PMID: 16912295 [PubMed - indexed for MEDLINE]Related articlesFree article

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D.

Nature. 2003 Jul 3;424(6944):99-103. Epub 2003 May 28.PMID: 12808466 [PubMed - indexed for MEDLINE]Related articles

Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.

Browne EP, Allers C, Landau NR.

Virology. 2009 May 10;387(2):313-21. Epub 2009 Mar 21.PMID: 19304304 [PubMed - indexed for MEDLINE]Related articles

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.

Suspène R, Sommer P, Henry M, Ferris S, Guétard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP.

Nucleic Acids Res. 2004 Apr 30;32(8):2421-9. Print 2004.PMID: 15121899 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV-1 Vif and APOBEC3G: multiple roads to one goal.

Goncalves J, Santa-Marta M.

Retrovirology. 2004 Sep 21;1:28.PMID: 15383144 [PubMed - indexed for MEDLINE]Related articlesFree article

Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.

Russell RA, Pathak VK.

J Virol. 2007 Aug;81(15):8201-10. Epub 2007 May 23.PMID: 17522216 [PubMed - indexed for MEDLINE]Related articlesFree article

Dual effect of APOBEC3G on Hepatitis B virus.

Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Yatsuji H, Shirakawa K, Takaori-Kondo A, Chayama K.

J Gen Virol. 2007 Feb;88(Pt 2):432-40.PMID: 17251560 [PubMed - indexed for MEDLINE]Related articlesFree article

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13.PMID: 15829920 [PubMed - indexed for MEDLINE]Related articles

HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.

Santa-Marta M, Aires da Silva F, Fonseca AM, Rato S, Goncalves J.

Mol Immunol. 2007 Jan;44(4):583-90. Epub 2006 Mar 31.PMID: 16580072 [PubMed - indexed for MEDLINE]Related articles

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.PMID: 15168739 [PubMed - indexed for MEDLINE]Related articles

Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu XF.

J Virol. 2007 Jul;81(13):7238-48. Epub 2007 Apr 11.PMID: 17428847 [PubMed - indexed for MEDLINE]Related articlesFree article

Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.

Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK.

J Virol. 2007 Jul;81(13):7099-110. Epub 2007 Apr 11.PMID: 17428871 [PubMed - indexed for MEDLINE]Related articlesFree article